Literature DB >> 10953021

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.

J M Olefsky1.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10953021      PMCID： PMC380259          DOI： 10.1172/JCI10843

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  47 in total

1.  PPAR gamma is required for placental, cardiac, and adipose tissue development.

Authors:  Y Barak; M C Nelson; E S Ong; Y Z Jones; P Ruiz-Lozano; K R Chien; A Koder; R M Evans
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

Review 2.  Insulin resistance and cardiovascular disease.

Authors:  H N Ginsberg
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 3.  Insights into insulin resistance and type 2 diabetes from knockout mouse models.

Authors:  T Kadowaki
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

4.  Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Authors:  I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

Review 5.  Thiazolidinediones in the treatment of insulin resistance and type II diabetes.

Authors:  A R Saltiel; J M Olefsky
Journal:  Diabetes       Date:  1996-12       Impact factor: 9.461

6.  Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.

Authors:  H S Camp; O Li; S C Wise; Y H Hong; C L Frankowski; X Shen; R Vanbogelen; T Leff
Journal:  Diabetes       Date:  2000-04       Impact factor: 9.461

7.  Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase.

Authors:  L Nagy; H Y Kao; D Chakravarti; R J Lin; C A Hassig; D E Ayer; S L Schreiber; R M Evans
Journal:  Cell       Date:  1997-05-02       Impact factor: 41.582

8.  TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone.

Authors:  P D Miles; O M Romeo; K Higo; A Cohen; K Rafaat; J M Olefsky
Journal:  Diabetes       Date:  1997-11       Impact factor: 9.461

9.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.

Authors:  S A Kliewer; B M Forman; B Blumberg; E S Ong; U Borgmeyer; D J Mangelsdorf; K Umesono; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

10.  Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.

Authors:  M K Lee; P D Miles; M Khoursheed; K M Gao; A R Moossa; J M Olefsky
Journal:  Diabetes       Date:  1994-12       Impact factor: 9.461
View more
  129 in total

1.  Unraveling the mechanism of action of thiazolidinediones.

Authors:  C R Kahn; L Chen; S E Cohen
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

2.  PPARgamma and insulin sensitivity: too much and too little of a good thing.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2001-11-27       Impact factor: 4.599

3.  Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache.

Authors:  E D Rosen; B M Spiegelman
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 4.  Obesity and insulin resistance.

Authors:  B B Kahn; J S Flier
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

5.  PPARG regulates gonadotropin-releasing hormone signaling in LbetaT2 cells in vitro and pituitary gonadotroph function in vivo in mice.

Authors:  Shweta Sharma; Prem M Sharma; Devendra S Mistry; R Jeffery Chang; Jerrold M Olefsky; Pamela L Mellon; Nicholas J G Webster
Journal:  Biol Reprod       Date:  2010-11-10       Impact factor: 4.285

6.  Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes.

Authors:  R Hernandez; T Teruel; M Lorenzo
Journal:  Diabetologia       Date:  2003-11-01       Impact factor: 10.122

7.  The PPARγ2 P12A polymorphism is not associated with all-cause mortality in patients with type 2 diabetes mellitus.

Authors:  Antonio Pacilli; Sabrina Prudente; Massimiliano Copetti; Andrea Fontana; Luana Mercuri; Simonetta Bacci; Antonella Marucci; Federica Alberico; Raffaella Viti; Antonio Palena; Olga Lamacchia; Mauro Cignarelli; Salvatore De Cosmo; Vincenzo Trischitta
Journal:  Endocrine       Date:  2016-03-08       Impact factor: 3.633

8.  Synthesis and anti-obesity effects in vivo of Crotadihydrofuran C as a novel PPARγ antagonist from Crotalaria albida.

Authors:  Qin-Hu Sun; Yu Zhang; Gui-Xin Chou
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

9.  Liver X receptor agonists ameliorate TNFalpha-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression.

Authors:  S Fernández-Veledo; I Nieto-Vazquez; C M Rondinone; M Lorenzo
Journal:  Diabetologia       Date:  2006-10-27       Impact factor: 10.122

10.  Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells.

Authors:  Elisabetta Ceni; Tommaso Mello; Mirko Tarocchi; David-W Crabb; Anna Caldini; Pietro Invernizzi; Calogero Surrenti; Stefano Milani; Andrea Galli
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.